Pleased to share our study -"Trends in Incidence & Survival Outcomes in Small Cell Lung Cancer Patients" ➡️SCLC cases have gradually declined, now comprising 11.2% of all lung cancers @OncoAlert #LCSM @BTFCancerNews @aniroulaMD @kaushalpar @thadid1 https://t.co/rC5Vy1A578

Trainees & junior faculty: the #TexasLung26 Poster Competition is open - winners will receive registration, travel, and accommodation to the 2026 Texas Lung Cancer Conference at Austin City Limits, April 9-11, 2026. Submit today! Details at https://t.co/23wG464LxK

🙏🌟It’s been one of the MOST rewarding experiences of my #Academic Career to serve as the: ❇️#Chair of the #Oncology #Training Programs (OTP) #Committee of @ASCO. My term, during which I worked with AMAZING colleagues & GREAT #ASCO Staff, was completed by chairing the:

Hey ID Fellows, what are your favorite ID consults? Asked that question during a recent visit to the ID division at Johns Hopkins, and here's what their fellows said.

🔥🚨#November is 🫁 #LungCancerAwareness Month. Lung Cancer Awareness #SavesLives. Together, WITH #Patients, we keep the #Fight against #LungCancer. We have made a great #Progress but still have a long way to go. #LCAM25 👇🏼Sharing, like every year, my #AWARENESS #Mnemonic

🔥🚨@OncoAlert Hot Off The Press. Just published @NEJM in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#OptiTROP-Lung04 phase 3 trial of: ⭐️#Sacituzumab tirumotecan (#TROP2 #ADC) VS #Chemotherapy in advanced #EGFR mutant non-small cell #LungCancer after

🔥🚨@OncoAlert Hot Off The Press. Just published @TheLancet in conjunction with presentation @myESMO #ESMO25 Results of: 🎯#HARMONi-6 phase 3 trial of: ⭐️#Ivonescimab + #Chemotherapy VS #Tislelizumab + #Chemotherapy as 1st line Tx for advanced #Squamous non-small-cell

Dr. Pedro Simoes da Rocha at #ESMO25 presents intracranial efficacy of ifinatamab deruxtecan (I-DXd, B7-H3 ADC) in #SCLC. Intracranial RR 46.2% (among pts with no prior radiation, icRR 57.7% and in pts with no brain mets, only 12.5% had CNS progression. #ESMOAmbassadors

🆙#ESMO25🇩🇪 🔥#LCSM Mini Oral, non-mets, SCLC ☑️DeLLphi-304: Safety analysis of phase III study to evaluate tarlatamab versus chemotherapy for previously treated SCLC ☑️All G AEs: Anemia 19.8%, Neutropenia 7.5% 🎙️ Dr. Martin H. Schuler @OncoAlert @myESMO @Larvol

💥 anti-TIGIT fails again (I can’t remember how many times I have posted negative results of these agents) 🏙️ Tiragolumab + atezolizumab did not improve PFS versus durvalumab in unresectable stage III NSCLC after chemoradiation in SKYSCRAPER-03 trial. #LCSM #ESMO25

Dr. @NReguart discusses tarlatamab in #SCLC at #ESMO25. Outlines rationale and very reassuring to see consistency from other efforts. Will use of T Cell engagers be the future for all eligible patients with SCLC? #ESMOAmbassadors

🔥 #ESMO25 🇩🇪 🔥 #LCSM Proffered paper, mets ☑️SOHO-01: Sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer ☑️mPFS (PreTx w/o HER2, Pre HER2-ADC, Tx-naive): 8.3m, 5.5m, and not reached 🎙️ @LeXiuning @OncoAlert @myESMO @Larvol

BEAMION-Lung01; 1st line dataset from cohort 2; zongo 120mg od; stable and or asymptomatic bm; n=74; 66% YVMA; ORR 77%; DCR 96%; responses early; no new toxicity signals; 3% ILD (mild) #ESMO25

🔥 #ESMO25 🇩🇪 🔥 #LCSM Proffered paper, mets ☑️Beamion LUNG 1: Zongertinib as first-line treatment in patients with advanced HER2-mutant NSCLC ☑️ORR 77%, 6m DoR 80%, 6m PFS 79% 🎙️ @DrSanjayPopat @OncoAlert @myESMO @Larvol

ALEX trial 1st L alectinib (vs crizo) not ⬆️OS but trial not powered for OS. The best drug first? living w/o disease PD and good control of risk of brain PD count most!!Today lorlatinib is one SoC, futute SoC in 1st line Neladalkib (NVL655), ALKZAR trial vs alectinib?. #ESMO25

PACIFIC-2 @JCO_ASCO ➡️Pts with unresectable stage III NSCLC randomized (2:1) to durvalumab or placebo from the start of concurrent chemo-RT ➡️No difference in PFS and OS #LCSM @OncoAlert @BTFCancerNews https://t.co/7PzFLbgGBp

It’s happening @myESMO #ESMO25

HER2 TKI for HER2m NSCLC are real again Zongeritinib (the 2nd xombie 🧟‍♂️) outstanding activity in 1st Line (n=74, 30% Brain mets) with most G1-2 AEs (better safety than sebavertinib) Ready to replace 1st line CTIO? Awaiting for the ph3 trial BeamionLung02 zonge vs SoC #ESMO25

FLAURA-2 @NEJM ➡️Pts w/ advanced NSCLC randomized to osimertinib versus chemo plus Osi ➡️↑ OS with chemo plus osi (Md OS: 47.5 mo vs. 37.6 mo; HR: 0.77) @OncoAlert @BTFCancerNews #LCSM https://t.co/IDiTEh1aBL

Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer @NEJM ➡️ORR 38%-71% Md DoR 8.3-11 mo #LCSM @OncoAlert @BTFCancerNews https://t.co/yGP54wRC6K

🚨🔥@OncoAlert Hot Off The Press Just published @NEJM #OverallSurvival data from: ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC). ✅Impressive Statistically Significant & Clinically